$RSLS
ReShape Lifesciences Inc. Stock $rsls

$rsls Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000142757018000088 Filed on November 02, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q4
Revenue	$2.036M	$2.987M	$3.692M
YoY Change	-44.85%	7.18%	378.24%
Cost Of Revenue	$164.3K	$1.418M	$30.00K
YoY Change	447.67%	7.91%	-66.67%
Gross Profit	$532.0K	$1.569M	$1.990M
YoY Change	-73.27%	6.52%	-2110.1%
Gross Profit Margin	26.13%	52.53%	53.9%
Selling, General & Admin	$19.26M	$5.836M	$6.760M
YoY Change	184.94%	-25.3%	133.91%
% of Gross Profit	3620.62%	371.96%	339.7%
Research & Development	$5.722M	$2.368M	$1.860M
YoY Change	207.64%	-15.37%	44.19%
% of Gross Profit	1075.59%	150.92%	93.47%
Depreciation & Amortization	-$1.849M	$800.0K	$120.0K
YoY Change	-1641.18%	899.98%	300.0%
% of Gross Profit	-347.64%	50.99%	6.03%
Operating Expenses	$38.99M	$8.204M	$8.620M
YoY Change	352.3%	-22.68%	106.22%
Operating Profit	-$8.660M	-$6.635M	-$9.922M
YoY Change	-12.72%	-27.39%	31.7%
Interest Expense	-$12.38K	-$70.00K	$280.0K
YoY Change	-104.42%	233.33%	-152.83%
% of Operating Profit
Other Income/Expense, Net	-$155.4K	-$40.00K	-$280.0K
YoY Change	-44.5%	263.64%	-227.27%
Pretax Income	-$38.71M	-$5.287M	-$8.580M
YoY Change	351.21%	-47.08%	93.68%
Income Tax	-$3.447M	-$531.0K	-$10.00K
% Of Pretax Income
Net Earnings	-$8.756M	-$6.745M	-$10.12M
YoY Change	-13.48%	-26.44%	35.02%
Net Earnings / Revenue	-430.06%	-225.81%	-274.11%
Basic Earnings Per Share
Diluted Earnings Per Share	-$8.707B	-$3.228B	-$100.7B
COMMON SHARES
Basic Shares Outstanding	23.28M shares	17.82M shares	17.44M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.548M	$472.9K	$10.16M
YoY Change	-45.4%	-97.98%	206.95%
Cash & Equivalents	$21.19M	$21.55M	$21.11M
Short-Term Investments	$2.500M	$8.100M	$23.30M
Other Short-Term Assets	$2.462M	$909.0K	$1.714M
YoY Change	43.64%	-9.64%	37.78%
Inventory	$1.580M	$1.955M	$1.418M
Prepaid Expenses	$2.329M	$783.0K	$1.514M
Receivables	$870.0K	$2.775M	$4.223M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$28.65M	$35.31M	$51.76M
YoY Change	-44.65%	-38.92%	-33.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.739M	$1.572M	$1.346M
YoY Change	29.2%	23.39%	87.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$562.9K	$81.76K	$990.0K
YoY Change	-43.15%	-92.83%	-11.61%
Total Long-Term Assets	$1.739M	$1.572M	$1.346M
YoY Change	29.2%	23.39%	87.73%
TOTAL ASSETS
Total Short-Term Assets	$28.65M	$35.31M	$51.76M
Total Long-Term Assets	$1.739M	$1.572M	$1.346M
Total Assets	$30.39M	$36.88M	$53.10M
YoY Change	-42.78%	-37.58%	-32.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.159M	$1.458M	$1.276M
YoY Change	-9.17%	105.35%	114.45%
Accrued Expenses	$4.829M	$4.409M	$5.960M
YoY Change	-18.97%	28.53%	116.73%
Deferred Revenue	$352.0K	$301.0K	$510.0K
YoY Change	-30.98%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.930M	$523.0K	$1.958M
YoY Change	407.15%	-45.35%
Total Short-Term Liabilities	$17.23M	$7.281M	$10.01M
YoY Change	72.12%	10.64%	118.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$9.399M	$7.964M
YoY Change	-100.0%	4.96%	-19.4%
Other Long-Term Liabilities	$48.00K	$70.00	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$48.00K	$9.445M	$7.977M
YoY Change	-99.4%	5.17%	-19.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.23M	$7.281M	$10.01M
Total Long-Term Liabilities	$48.00K	$9.445M	$7.977M
Total Liabilities	$17.28M	$16.73M	$17.99M
YoY Change	-3.94%	7.48%	24.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$148.8M	-$140.0M	-$111.4M
YoY Change	33.56%	38.2%	45.38%
Common Stock	$161.9M	$160.2M	$146.5M
YoY Change	10.49%	10.62%	3.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.11M	$20.15M	$35.11M
YoY Change
Total Liabilities & Shareholders Equity	$30.39M	$36.88M	$53.10M
YoY Change	-42.78%	-37.58%	-32.59%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q4
OPERATING ACTIVITIES
Net Income	-$8.756M	-$6.745M	-$10.12M
YoY Change	-13.48%	-26.44%	35.02%
Depreciation, Depletion And Amortization	-$1.849M	$800.0K	$120.0K
YoY Change	-1641.18%	899.98%	300.0%
Cash From Operating Activities	-$7.090M	-$4.581M	-$8.860M
YoY Change	-19.98%	-18.79%	150.28%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$10.00K	-$30.00K
YoY Change	-100.0%	-110.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$4.380M
YoY Change	-100.0%		-147.1%
Cash From Investing Activities	-$10.32M	$2.970K	-$4.410M
YoY Change	134.04%	-102.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	22.49M	3.187M	0.000
YoY Change		-82.27%
NET CHANGE
Cash From Operating Activities	-7.090M	-4.581M	-8.860M
Cash From Investing Activities	-10.32M	2.970K	-4.410M
Cash From Financing Activities	22.49M	3.187M	0.000
Net Change In Cash	5.075M	-1.390M	-13.27M
YoY Change	-138.24%	-111.37%	274.86%
FREE CASH FLOW
Cash From Operating Activities	-$7.090M	-$4.581M	-$8.860M
Capital Expenditures	$0.00	$10.00K	-$30.00K
Free Cash Flow	-$7.090M	-$4.591M	-$8.830M
YoY Change	-19.71%	-17.14%	149.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001427570
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23280439	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	OBALON THERAPEUTICS INC
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Trading Symbol TradingSymbol	OBLN
CY2017Q4	obln	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	0	USD
CY2018Q3	obln	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	65000	USD
CY2017Q4	obln	Accrued Customer Incentives Current AccruedCustomerIncentivesCurrent	558000	USD
CY2018Q3	obln	Accrued Customer Incentives Current AccruedCustomerIncentivesCurrent	903000	USD
CY2017Q4	obln	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	289000	USD
CY2018Q3	obln	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	346000	USD
CY2018Q2	obln	Operating Leases Additional Leased Square Feet OperatingLeasesAdditionalLeasedSquareFeet	2700	sqft
CY2018Q3	obln	Revenue Recognition Sales Returns Reserve RevenueRecognitionSalesReturnsReserve	200000	USD
	obln	Unpaid Stock Issuance Costs UnpaidStockIssuanceCosts	0	USD
	obln	Unpaid Stock Issuance Costs UnpaidStockIssuanceCosts	160000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1276000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1458000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4223000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2775000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-24000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	20000	USD
CY2017Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	60000	USD
CY2018Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	6000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1415000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1826000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	146474000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	160130000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	239000	USD
CY2018Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	538000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	31000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	29000	USD
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	873282	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	904755	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	259683	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	424725	shares
CY2017Q4	us-gaap	Assets Assets	53101000	USD
CY2018Q3	us-gaap	Assets Assets	36879000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	51755000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	35307000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	23295000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	8118000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	23292000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	8116000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	126000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	106000	USD
CY2018Q3	us-gaap	Capitalized Contract Cost Amortization Period CapitalizedContractCostAmortizationPeriod	P1Y
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72975000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12083000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21108000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21552000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-60892000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	444000	USD
CY2018Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.1918
CY2018Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	24224	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4955218	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17500604	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23280310	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17500604	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23280310	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	23000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9155000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24648000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6748000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28621000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	510000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	301000	USD
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1314000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3127000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1418000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3919000	USD
CY2018Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10000000	USD
CY2018Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	78000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	13000	USD
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	46000	USD
CY2017Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	221000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.48
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000	USD
CY2018Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	428000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-110000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.60
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4494000	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2671000	USD
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6600000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y12M6D
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-107000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	1473000	USD
	us-gaap	Gross Profit GrossProfit	3095000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	1569000	USD
	us-gaap	Gross Profit GrossProfit	3146000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	534000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	135000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2515000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1448000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	72000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-209000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-515000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	0	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	174000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1823000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	84000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	537000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-240000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-805000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	506000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	634000	USD
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-21000	USD
CY2018Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-70000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-164000	USD
	us-gaap	Interest Paid Net InterestPaidNet	416000	USD
	us-gaap	Interest Paid Net InterestPaidNet	473000	USD
CY2017Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	85000	USD
CY2018Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	5000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	245000	USD
CY2018Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	496000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	1418000	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	1955000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1046000	USD
CY2018Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1269000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	127000	USD
CY2018Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	190000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1398000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2017Q4	us-gaap	Liabilities Liabilities	17988000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	16726000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53101000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36879000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10011000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7281000	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7977000	USD
CY2018Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9445000	USD
CY2018Q3	us-gaap	Long Term Debt LongTermDebt	9922000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1958000	USD
CY2018Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	523000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7964000	USD
CY2018Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9399000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	256000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10129000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39721000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14332000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21427000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24017000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-9170000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-24645000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-6745000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28624000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	10611000	USD
	us-gaap	Operating Expenses OperatingExpenses	27564000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	8204000	USD
	us-gaap	Operating Expenses OperatingExpenses	31451000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9138000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24469000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6635000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-28305000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1705000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	126000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	501000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	487000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	474000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	117000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	699000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	875000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1714000	USD
CY2018Q3	us-gaap	Other Assets Current OtherAssetsCurrent	909000	USD
CY2017Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	115000	USD
CY2018Q3	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	121000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	15000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1773000	USD
CY2018Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2328000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-66000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-40000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-155000	USD
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	0	USD
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	30000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	904000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	867000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	80317000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	9103000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1514000	USD
CY2018Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	783000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9973000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	41500000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	24302000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	46000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	38000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	210000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	148000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2761000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3398000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1346000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1572000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2798000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7958000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2368000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8359000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111374000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-139998000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-140000000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2800000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2787000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6200000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6222000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2987000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3000000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7065000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7100000	USD
	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	three to six months
CY2017Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	167000	USD
CY2018Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	133000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7813000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19606000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5836000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23092000	USD
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1023000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2102000	USD
CY2018Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1007000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3610000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	212000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	10.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	425942	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.10
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	413000	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	626942	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	9.98
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.99
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	957238	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1565864	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1194000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2979285	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3561908	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.49
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.88
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	845000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1662409	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	5.93
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1168000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3327958	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.85
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.46
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.32
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.92
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y7M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M6D
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	23292000	USD
CY2018Q3	us-gaap	Short Term Investments ShortTermInvestments	8116000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	26003	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	35113000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	20153000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16747791	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16649447	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19457971	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17837297	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and trade accounts receivable, which are generally not collateralized. The Company limits its exposure to credit loss by placing its cash equivalents with high credit quality financial institutions and investing in high quality short-term debt instruments. The Company’s customers consist of physicians and institutions in the United States and one international distributor. The Company establishes customer credit policies related to its accounts receivable based on historical collection experiences within the various markets in which the Company operates, historical past-due amounts, and any specific information that the Company becomes aware of such as bankruptcy or liquidity issues of customers. </font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font></div></div>

Files In Submission

Name	View Source	Status
0001427570-18-000088-index-headers.html	Edgar Link	pending
0001427570-18-000088-index.html	Edgar Link	pending
0001427570-18-000088.txt	Edgar Link	pending
0001427570-18-000088-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
obln-20180930.xml	Edgar Link	completed
obln-20180930.xsd	Edgar Link	pending
obln-20180930_cal.xml	Edgar Link	unprocessable
obln-20180930_def.xml	Edgar Link	unprocessable
obln-20180930_lab.xml	Edgar Link	unprocessable
obln-20180930_pre.xml	Edgar Link	unprocessable
obln-93018x10q.htm	Edgar Link	pending
obln311-93018.htm	Edgar Link	pending
obln312-93018.htm	Edgar Link	pending
obln321-93018.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RSLS
ReShape Lifesciences Inc. Stock $rsls

2018 Q4 Form 10-Q Financial Statement

#000142757018000088 Filed on November 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS ReShape Lifesciences Inc. Stock $rsls

2018 Q4 Form 10-Q Financial Statement

#000142757018000088 Filed on November 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS
ReShape Lifesciences Inc. Stock $rsls